AU5920400A - Cell-based assay systems for examining hcv ns3 protease activity - Google Patents
Cell-based assay systems for examining hcv ns3 protease activityInfo
- Publication number
- AU5920400A AU5920400A AU59204/00A AU5920400A AU5920400A AU 5920400 A AU5920400 A AU 5920400A AU 59204/00 A AU59204/00 A AU 59204/00A AU 5920400 A AU5920400 A AU 5920400A AU 5920400 A AU5920400 A AU 5920400A
- Authority
- AU
- Australia
- Prior art keywords
- cell
- protease activity
- based assay
- assay systems
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 238000000423 cell based assay Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14256199P | 1999-07-07 | 1999-07-07 | |
US60142561 | 1999-07-07 | ||
PCT/US2000/018590 WO2001002601A2 (en) | 1999-07-07 | 2000-07-07 | Cell-based assay systems for examining hcv ns3 protease activity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5920400A true AU5920400A (en) | 2001-01-22 |
Family
ID=22500325
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU59204/00A Abandoned AU5920400A (en) | 1999-07-07 | 2000-07-07 | Cell-based assay systems for examining hcv ns3 protease activity |
AU57888/00A Abandoned AU5788800A (en) | 1999-07-07 | 2000-07-07 | Peptide boronic acid inhibitors of hepatitis c virus protease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU57888/00A Abandoned AU5788800A (en) | 1999-07-07 | 2000-07-07 | Peptide boronic acid inhibitors of hepatitis c virus protease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1196436A2 (en) |
AU (2) | AU5920400A (en) |
CA (1) | CA2376965A1 (en) |
WO (2) | WO2001002601A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048116A2 (en) * | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
US6586615B1 (en) | 2001-01-10 | 2003-07-01 | Bristol-Myers Squibb Company | α-aminoboronic acids prepared by novel synthetic methods |
PT1355910E (en) | 2001-01-25 | 2011-03-24 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Formulation of boronic acid compounds |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
BR0314450A (en) | 2002-09-09 | 2005-07-26 | Trigen Ltd | Salts of boronic acid with the addition of a pharmaceutically acceptable base, pharmaceutical formulation, and use of said salts to prepare a pharmaceutical formulation. |
US20050288253A1 (en) | 2002-09-09 | 2005-12-29 | Trigen Limited | Boronic acid salts |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
ATE547412T1 (en) * | 2003-04-11 | 2012-03-15 | Vertex Pharma | INHIBITORS OF SERINE PROTEASES, IN PARTICULAR HCV NS3-NS4A PROTEASE |
US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
EA009295B1 (en) | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Hepatitis c inhibitor compounds |
WO2005024051A1 (en) * | 2003-06-23 | 2005-03-17 | Vanderbilt University | Cell-based assay for identifying peptidase inhibitors |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
AR045596A1 (en) * | 2003-09-05 | 2005-11-02 | Vertex Pharma | INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A |
MXPA06003141A (en) | 2003-09-22 | 2006-06-05 | Boehringer Ingelheim Int | Macrocyclic peptides active against the hepatitis c virus. |
ES2358333T3 (en) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | MACROCYCLIC PEPTIDES WITH ACTION AGAINST THE VIRUS OF HEPATITIS C. |
DE602005023965D1 (en) | 2004-03-08 | 2010-11-18 | Prosidion Ltd | PYRROLOPYRIDINE-2-CARBOXYLIC HYDRAZIDE AS INHIBITORS OF GLYCOPE PHOSPHORYLASE |
MXPA06014417A (en) * | 2004-06-14 | 2007-03-08 | Anacor Pharmaceuticals Inc | Anti-viral uses of borinic acid complexes. |
UY29016A1 (en) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C |
EP1771454B1 (en) | 2004-07-20 | 2011-06-15 | Boehringer Ingelheim International GmbH | Hepatitis c inhibitor peptide analogs |
WO2006059164A2 (en) | 2004-12-02 | 2006-06-08 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
WO2006102760A1 (en) * | 2005-04-01 | 2006-10-05 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2009503084A (en) * | 2005-08-01 | 2009-01-29 | フェノミックス コーポレーション | Hepatitis C serine protease inhibitor and use thereof |
WO2007137080A2 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
US20100120716A1 (en) * | 2006-12-06 | 2010-05-13 | Phenomix Corporation | Macrocyclic hepatitis c serine protease inhibitors and uses therefor |
JP2010518099A (en) | 2007-02-09 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as channel activating protease inhibitors |
US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
EA027346B1 (en) | 2008-06-17 | 2017-07-31 | Милленниум Фармасьютикалз, Инк. | Boronate ester compounds and pharmaceutical compositions thereof |
AR075090A1 (en) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
EP2516449A1 (en) | 2009-12-22 | 2012-10-31 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
TW201138786A (en) * | 2010-02-19 | 2011-11-16 | Glaxo Group Ltd | Therapeutic compounds |
CN107266485A (en) | 2010-03-31 | 2017-10-20 | 米伦纽姆医药公司 | The cyclopropyl second boronic acid derivatives of 1 amino 2 |
WO2012067663A1 (en) * | 2010-11-18 | 2012-05-24 | Glaxo Group Limited | Compounds |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US9119868B2 (en) * | 2011-08-17 | 2015-09-01 | Glaxosmithkline Llc | Therapeutic methods |
RS55462B1 (en) * | 2011-08-19 | 2017-04-28 | Glaxo Group Ltd | Benzofuran compounds for the treatment of hepatitis c virus infections |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
NZ725948A (en) | 2014-05-20 | 2024-01-26 | Takeda Pharmaceuticals Co | Boron-containing proteasome inhibitors for use after primary cancer therapy |
US10294246B2 (en) * | 2014-10-01 | 2019-05-21 | Merck Patent Gmbh | Substituted boronic acids and boronate esters as immunoproteasome inhibitors |
MY186911A (en) * | 2014-10-01 | 2021-08-26 | Merck Patent Gmbh | Boronic acid derivatives |
US10253049B2 (en) * | 2014-10-01 | 2019-04-09 | Merck Patent Gmbh | Boronic acid derivatives |
JP7179721B2 (en) | 2016-06-21 | 2022-11-29 | オリオン・オフサルモロジー・エルエルシー | Heterocyclic prolinamide derivative |
EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
CA3179181A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599906A (en) * | 1990-04-13 | 1997-02-04 | Schering Corporation | Protease assays |
IT1272179B (en) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV. |
US5861267A (en) * | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
KR100209095B1 (en) * | 1996-06-28 | 1999-07-15 | 성재갑 | Substitution hepatitis c virus which can be used for detecting the activity of the hcv protease, and recombinant gene and use |
UA79749C2 (en) * | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
WO1998037180A2 (en) * | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
EP1003775B1 (en) * | 1997-08-11 | 2005-03-16 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
US6280940B1 (en) * | 1998-08-05 | 2001-08-28 | Agouron Pharmaceuticals, Inc. | Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease |
MXPA01011045A (en) * | 1999-05-04 | 2002-07-22 | Boehringer Ingelheim Ltd | Surrogate cell-based system and method for assaying the activity of hepatitis c virus ns3 protease. |
-
2000
- 2000-07-07 EP EP00943413A patent/EP1196436A2/en not_active Withdrawn
- 2000-07-07 WO PCT/US2000/018590 patent/WO2001002601A2/en active Application Filing
- 2000-07-07 AU AU59204/00A patent/AU5920400A/en not_active Abandoned
- 2000-07-07 AU AU57888/00A patent/AU5788800A/en not_active Abandoned
- 2000-07-07 WO PCT/US2000/018655 patent/WO2001002424A2/en not_active Application Discontinuation
- 2000-07-07 CA CA002376965A patent/CA2376965A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001002424A2 (en) | 2001-01-11 |
CA2376965A1 (en) | 2001-01-11 |
WO2001002601A2 (en) | 2001-01-11 |
AU5788800A (en) | 2001-01-22 |
WO2001002601A3 (en) | 2001-07-26 |
EP1196436A2 (en) | 2002-04-17 |
WO2001002424A3 (en) | 2001-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5920400A (en) | Cell-based assay systems for examining hcv ns3 protease activity | |
AU7063598A (en) | Hepatitis c ns3 protease inhibitors | |
AUPR005600A0 (en) | Diagnostic assay | |
AU2001253206A1 (en) | Ns5b hcv polymerase inhibitors | |
AU3440900A (en) | Assay system | |
AUPP312998A0 (en) | Diagnostic assay | |
AU2001262906A1 (en) | Peptide biosensors for anthrax protease | |
AU6800100A (en) | Alpha regions | |
AU3465399A (en) | Diagnostic modified-nucleoside detection assay | |
AU3902099A (en) | Tethered function assay for protein function | |
HUP0200945A3 (en) | Surrogate cell-based system and method for assaying the activity of hapatitis c virus ns3 protease | |
AU5179400A (en) | Switching complex architecture and operation | |
AU2001244093A1 (en) | Enzyme tablets for cleaning improvement | |
EP0880602A4 (en) | Rapid microbial protease assay | |
AU2016100A (en) | New assay | |
AU4586700A (en) | Improved assay and reagents therefor | |
AU1531801A (en) | Novel assay | |
AU5763100A (en) | Non-destructive cell-based assay | |
AU7537400A (en) | Assay | |
AU2533299A (en) | Microbial assay | |
AU2001241714A1 (en) | Micro-label biological assay system | |
AU7618400A (en) | Human ubiquitin protease | |
AU2813800A (en) | High throughput assay | |
AU2312700A (en) | Detecting telomerase activity | |
EP1177279A4 (en) | Assay reagent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |